Pharmaceutical Investing Abeona Announces FDA Grants RMAT Designation to ABO-102 Gene Therapy in MPS IIIA
Pharmaceutical Investing Abeona Therapeutics Receives Orphan Drug Designation in the European Union for ABO-202 Gene Therapy Program in Batten Disease
Pharmaceutical Investing Abeona Therapeutics Receives FDA Rare Pediatric Disease Designation for ABO-202 Gene Therapy Program in CLN1 Disease
Agios Receives FDA Priority Review for New Drug Application: How are Gene Therapy Drug Approvals Impacting Stocks?
Pharmaceutical Investing Abeona Therapeutics Reports Top-Line Data from Phase 1/2 Gene Therapy Trial in MPS IIIA
AMENDED FROM SOURCE - Blue Sky Uranium Increases and Closes 2nd and Final Tranche of the Oversubscribed Non-Brokered Private Placement
